Introduction
Upper tract urothelial carcinomas (UTUCs), accounting for only 5% to 10% of urothelial carcinomas, are relatively uncommon compared to bladder cancer, but 60% of UTUCs are invasive at diagnosis. 1 UTUCs have a peak incidence in people aged 70 to 90 years. 2, 3 For localized disease, open radical nephroureterectomy with bladder cuff excision is the standard for high-risk UTUC. 4 UTUCs that invade the muscle wall usually have a poor prognosis, with a 5-year specific survival of < 50% for pT2/pT3 and < 10% for pT4. 5, 6 For metastatic disease, chemotherapy would be the main choice. 4, 7 However, there are insufficient data for recommendations currently. Platinum-based chemotherapy is expected to have similar efficacy as in bladder cancer. Furthermore, chemotherapy-related toxicities often require treatment cessation, particularly nephrotoxicity from platinum derivatives, and may reduce survival in patients with postoperative renal dysfunction. Newer, safer, and more effective agents are urgently required. We here report a case of metastatic UTUC with BRAF V600E mutation by next-generation sequencing. The condition of the patient dramatically improved after administration of the BRAF inhibitor vemurafenib. To our knowledge, this is the first case of UTUC that responded to vemurafenib.
Case Report
A 60-year-old woman was diagnosed with ureteral cancer due to painless hematuria in April 2011. The study was approved by the Medical Ethics Committee of Navy General Hospital. Written
Clinical Practice Points
Upper tract urothelial carcinomas (UTUCs) are relatively uncommon compared to bladder cancer, but 60% of UTUCs are invasive at diagnosis. UTUCs are considered to be chemosensitive to platinum-based chemotherapy as bladder cancer; however, not all patients could receive chemotherapy because of chemotherapy-related toxicities. Furthermore, there are no validated second-or third-line chemotherapy regimens. Greater understandings of the molecular mechanisms of malignancies have led to the development of targeted therapy; furthermore, extraordinary advancements in sequencing technology have made it the potential for practical use in a clinical setting.
BRAF has become an important therapeutic target for patients with advanced malignant melanoma. The BRAF protein is normally involved in regulating cell growth. However, mutated BRAF triggers overactive downstream signaling in the absence of typical growth factors, leading to cell proliferation and survival. This case report describes the use of vemurafenib, a selective inhibitor of mutated BRAF, in a patient with metastatic UTUC with BRAF V600E mutation. Vemurafenib resulted in months of disease control. The case illustrates the effectiveness of nextgeneration sequencing in clinical settings, especially when conventional therapy is no longer effective; and it suggests that vemurafenib could be a new option for the treatment of UTUC with BRAF V600E mutation.
informed consent was obtained from the patient before publication of this case report.
Abdominal computed tomography (CT) revealed a spherical mass at the inferior segment of left ureter near the opening with a diameter 11 mm.
Surgery was carried out in May, 2011. Postoperative pathology revealed urothelial (transitional cell, papillary) carcinoma of the ureter, G3 with part G2, and invasion of the mucosal lamina. The patient received regular follow-up every 3 to 6 months. No metastases or recurrences were discovered until 2015.
On February 20, 2015, the patient complained of pain around the vagina, and ultrasound revealed a perineal mass. Ultrasoundguided biopsy was carried out, and pathology revealed transitional cell carcinoma (G3). In addition, whole-body positron emission tomography/CT further confirmed local recurrence of carcinoma of the left ureter as well as multiple metastatic carcinomas of the lung and bones.
On March 3, 2015, platinum-based chemotherapy was initiated every 21 days for a total of 5 cycles. Chest and abdomen CT showed a partial response (according to Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria). However, the chemotherapy was stopped after the fifth cycle of chemotherapy because of severe vomiting and poor performance status.
In September 2015, the patient was transferred to a radiologist so she could undergo radiotherapy to treat severe pain that originated from iliac bone metastases. A total of 40 Gy was provided, and the pain was significantly relieved. However, the patient began to experience hypodynamia and anemia in October 2015, which was considered to be the result of severe bone marrow suppression. Though her status improved with an infusion of suspension red blood cells, on October 22, 2015, the patient complained of recurrent pain worse than before, and a dose of oxycodone hydrochloride prolonged-release tablets (OxyContin) was adjusted to 480 mg every 12 hours, which resulted in lethargy. However, the pain was still poorly controlled, with a numeric pain intensity scale score of 10. The patient was considered to have progressive disease. Cytotoxic chemotherapy could not be provided because of her poor performance status and severe bone marrow suppression.
Next-generation sequencing was carried out, and the result revealed BRAF V600E mutation. After the patient provided written informed consent, the BRAF inhibitor vemurafenib was given at a dosage of 720 mg 2 times a day. After 2 weeks of targeted therapy, the pain was relieved significantly, and the dose of oxycodone hydrochloride reduced to 320 mg. This was considered an obvious clinical response. The pain was reevaluated by the numeric pain intensity scale assessment system to be reduced from 10 to < 3. Lung CT 1 month after the vemurafenib therapy revealed stable disease (lesion of decreased size). The patient then continued vemurafenib as maintenance therapy.
The toxicities the patient experienced were mainly nonhematologic toxicities, including skin rash and fatigue. No severe toxicities (grade 3/4) or other treatment-related adverse events were reported or detected.
The disease progressed in July 2016, with new metastases next to the greater psoas muscle found by enhanced magnetic resonance imaging. The progression-free survival time was more than 4 months without major toxic effects.
Discussion
Invasive UTUCs has a poor prognosis. The median survival for patients with stage T4 disease is only 6 months. 8 Surgery represents the only potentially curable therapeutic intervention for these patients. However, systemic recurrences are common in this disease. 9 In advanced-stage disease, the standard treatment is chemotherapy. UTUCs are considered to be relatively chemosensitive, as are those of the bladder. 10 Because of the low frequency of these tumors, 11 randomized clinical trials comparing the outcomes of different treatment modalities in patients with UTUCs are not available. Most of the data are based on outcomes from the treatment of bladder cancer, and the existing guidelines concerning the use of chemotherapy in UTUCs are based on expert opinion rather than on evidence-based data. 11, 12 According to the European Association of Urology treatment guidelines, 12 the chemotherapeutic regimens suggested for patients with UTUCs are the same as those for bladder cancer. Cisplatin-containing combination chemotherapeutic regimens have been the standard regimen since the late 1980s. 13 In the present case, the patient could not tolerate toxic chemotherapy because of her poor performance status. Next-generation sequencing was carried out and revealed the BRAF V600E mutation.
BRAF has become an important therapeutic target for patients with advanced malignant melanoma. The BRAF protein is normally involved in regulating cell growth. However, mutated BRAF triggers overactive downstream signaling in the absence of typical growth factors, leading to cell proliferation and survival. Vemurafenib is the first selective inhibitor of mutated BRAF and was approved by the US Food and Drug Administration for the treatment of metastatic or unresectable melanoma with BRAF V600E mutation in August 2011. It could inhibit oncogenic BRAF by binding to V600E, which renders the protein inactive, inhibiting downstream proliferation and signaling, ultimately leading to cancer cell apoptosis. 14 In addition to melanoma, vemurafenib has also been proved effective in some nonmelanoma cancers that carried BRAF V600 mutation. 15 However, no case has been reported in urothelial carcinoma. In this case, the patient manifested an obvious clinical response at 2 weeks after receipt of vemurafenib, with her pain relieved significantly. The administration of vemurafenib resulted in welltolerated toxic profiles. The treatment resulted in a progressionfree survival of more than 4 months without major toxic effects.
To our knowledge, this is the first report of the use of vemurafenib for UTUC. Vemurafenib could be a new option for the treatment of UTUC. Further studies are needed to optimize the treatment.
Conclusion
For UTUC with BRAF V600E mutation, vemurafenib may provide an additional option. Nevertheless, further large-scale prospective studies are required to improve its application in the treatment of UTUC.
